Halozyme Therapeutics Inc (HALO) Profitability Comparisons, Net Margin, Gross Margin, Tax rate, Cash Flow Margin Comparisons - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Gross Margin
• EBITDA Margin
• Operating Margin
• Net Margin
• Pre-Tax Margin
• Effective Tax Rate
• Free Cash Flow Margin
• Cash Flow Margin
Halozyme Therapeutics Inc   (NASDAQ: HALO)

Halozyme Therapeutics Inc Profitability Comparisons

Select each Category to receive further Information



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

HALO Profitability Ratio

 Company Industry Sector S&P 500
Gross Profit Margin (Q2 MRQ) 83.54 % 71.11 % 65.43 % 46.08 %
Gross Margin (Q2 TTM) 82.42 % 73.28 % 65.99 % 46.29 %
Gross Profit Margin 5 Yr. Avg. 81.05 % 70.97 % 65.55 % 48.95 %
EBITDA Margin (Q2 MRQ) 66.76 % 20.66 % 18.97 % 20.47 %
EBITDA Margin (Q2 TTM) 42.13 % 26.3 % 21 % 20.12 %
EBITDA Margin 5 Yr. Avg. 53.6 % 22.79 % 31.38 % 23.41 %
Operating Margin (Q2 MRQ) 59.8 % 11.28 % 16.57 % 16.05 %
Operating Margin (Q2 TTM) 35.9 % 15.22 % 17.81 % 16.34 %
Operating Margin 5 Yr. Avg. 46.27 % 6.03 % 14.33 % 19.26 %
Pre-Tax Profit Margin (Q2 MRQ) 59.23 % 7.4 % 10.93 % 13.96 %
Pre-Tax Profit Margin (Q2 TTM) 35.06 % 13.89 % 12.78 % 13.09 %
Pre-Tax Profit Margin 5 Yr. Avg. 44.81 % 9.88 % 10.37 % 13.52 %
Net Margin (Q2 MRQ) 47.8 % 2.64 % 8.14 % 11.42 %
Net Margin (Q2 TTM) 24.86 % 10.23 % 9.93 % 10.76 %
Net Margin 5 Yr. Avg. 44.37 % 6.58 % 6.08 % 10.8 %



Business Segment Profit Margin
 
Device licensing and development revenue
  Explore Device licensing and development revenue Segment  -
Product
  Explore Product Segment  -
Royalty
  Explore Royalty Segment  -
Collaborative Agreements
  Explore Collaborative Agreements Segment  -
Proprietary Products Sales
  Explore Proprietary Products Sales Segment  -
Bulk rHuPH20
  Explore Bulk rHuPH20 Segment  -
Device Partnered Products
  Explore Device Partnered Products Segment  -
Upfront Fees
  Explore Upfront Fees Segment  -
Device Licensing and Development
  Explore Device Licensing and Development Segment  -
 

Company's Cashflow Profitability & Other



Profitability Ratios Company Industry Sector S&P 500
Free Cash Flow Margin (Q2 MRQ) 49.21 % 1.35 % 0.21 % 1.39 %
Free Cash Flow Margin (Q2 TTM) 48.46 % 16.43 % 13.84 % 9.02 %
Free Cash Flow Margin 5 Yr. Avg. - 17.11 % 14.86 % 15.58 %
Net Cash Flow Margin (Q2 MRQ) 0 % 0.42 % -0.02 % 0.13 %
Net Cash Flow Margin (Q2 TTM) 15.04 % 4.6 % 0.14 % 1.9 %
Net Cash Flow Margin 5 Yr. Avg. - 10.89 % 3.16 % 6.44 %
Effective Tax Rate (Q2 MRQ) 19.3 % 63.94 % 25.41 % 18.83 %
Effective Tax Rate (Q2 TTM) 29.1 % 28.14 % 22.95 % 19.44 %
Effective Tax Rate 5 Yr. Avg. 5.67 % -399.76 % 20.51 % 19.76 %
Note
To view Detail Information & Trends click on Individual Category.
To see Industry, Sector or S&P 500 Performance, click on each Category respectivly, on the top of the Table.

For explanation of terms visit: Glossary
 




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.